NCT01538719View on ClinicalTrials.gov

IL1-TRAP, Rilonacept, in Systemic Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

August 11, 2017

Conditions
SclerodermaSystemic SclerosisDiffuse SclerodermaDiffuse Systemic Sclerosis
Interventions
DRUG

Rilonacept

Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks

OTHER

Placebo

Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks

Trial Locations (1)

02118

Boston University Medical Center, Boston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Boston University

OTHER

NCT01538719 - IL1-TRAP, Rilonacept, in Systemic Sclerosis | Biotech Hunter | Biotech Hunter